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ABSTRACT* 
Objective: To determine the direct financial impact 
for patients resulting from Medication Therapy 
Management (MTM) interventions made by 
community pharmacists. Secondary objectives 
include evaluating the patient and physician 
acceptance rates of the community pharmacists’ 
recommended MTM interventions. 
Methods: This was a retrospective observational 
study conducted at 20 Price Chopper and Hen 
House grocery store chain pharmacies in the 
Kansas City metro area from January 1, 2010 to 
December 31, 2010. Study patients were Medicare 
Part D beneficiaries eligible for MTM services. The 
primary outcome was the change in patient out-of-
pocket prescription medication expense as a result 
of MTM services. 
Results: Of 128 patients included in this study, 68% 
experienced no out-of-pocket financial impact on 
their medication expenses as a result of MTM 
services.  A total of 27% of the patients realized a 
cost-savings (USD440.50 per year, (SD=289.69)) 
while another 5% of patients saw a cost increase in 
out-of-pocket expense (USD255.66 per year, 
(SD=324.48)). The net financial impact for all 128 
patients who participated in MTM services was an 
average savings of USD102.83 per patient per year 
(SD=269.18, p<0.0001). Pharmacists attempted a 
total of 732 recommendations; 391 (53%) were 
accepted by both the patient and their prescriber. A 
total of 341 (47%) recommendations were not 
accepted because of patient refusal (290, 85%) or 
prescriber refusal (51, 15%). 
Conclusions: Patient participation in MTM services 
reduces patient out-of-pocket medication expense. 
However, this savings is driven by only 32% of 
subjects who are experiencing a financial impact on 
out-of-pocket medication expense. Additionally, the 
majority of the pharmacists’ recommended 
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SERVICIOS DE GESTIÓN DE LA 
MEDICACIÓN EN FARMACIA 
COMUNITARIA: IMPACTO FINANCIERO 
PARA LOS PACIENTES 
 
RESUMEN 
Objetivo: Determinar el impacto financiero directo 
para los pacientes resultando de las intervenciones 
de Gestión de la Medicación (MTM) hechas por 
farmacéuticos comunitarios. Los objetivos 
secundarios incluían evaluar las tasas de aceptación 
por pacientes y médicos de las recomendaciones de 
MTM de los farmacéuticos. 
Métodos: Fue un estudio observacional 
retrospectivo realizado en 20 tiendas de la cadena 
de farmacias Price Chopper and Hen House de la 
zona metropolitana de Kansas City desde 1 de 
enero 2010 a 31 de diciembre 2010. Los pacientes 
en estudio eran beneficiarios de Medicare Part D 
elegibles para servicios de MTM. El resultado 
primario fue los cambios en gastos sufragados por 
los pacientes de la medicación prescrita como 
resultado de los servicios de MTM. 
Resultados: De los 128 pacientes incluidos en el 
estudio, el 68% no experimentó impacto en sus 
gastos en medicación como resultado de los 
servicios de MTM. Un 27% de los pacientes 
consiguió un ahorro (USD440,50 por año, 
(SD=289,69)) mientras que otro 5% de pacientes 
vio incrementado su gasto en medicación 
(USD255,66 por año, (SD=324,48)). El impacto 
financiero neto para los 128 pacientes que 
participaron en el estudio fue un ahorro medio de 
USD102,83 por paciente y año (SD=269,18; 
p<0,0001). Los farmacéuticos intentaron un total de 
732 recomendaciones; 391 (53%) fueron aceptadas 
tanto por pacientes como por prescriptor. Un total 
de 341 (47%) recomendaciones no fueron 
aceptadas, por negativa del paciente (290; 85%) o 
por negativa del prescriptor (51; 15%). 
Conclusiones: La participación de los pacientes en 
servicios de MTM reduce el gasto en 
medicamentos del paciente. Sin embargo, este 
ahorro se materializa sólo en un 32% de pacientes 
que sufren impacto financiero. Asimismo, la 
mayoría (53%) de las intervenciones recomendadas 
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por el farmacéutico fueron aceptadas por pacientes 
y prescriptores. 
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Medicare is a United States federal health 
insurance for: individuals aged 65 years and older, 
individuals under age 65 years with certain 
disabilities and individuals at any age with End-
Stage Renal Disease (ESRD). Medicare provides 
hospital insurance (Medicare Part A), medical 
insurance (Medicare Part B) and prescription drug 
coverage (Medicare Part D) to those who qualify for 
benefits. Changes to the Medicare program were 
signed into law with the Medicare Prescription Drug, 
Improvement, and Modernization Act of 2003 (MMA 
2003).1 This legislation requires prescription drug 
plans to offer high-risk Medicare Part D 
beneficiaries Medication Therapy Management 
(MTM). For 2010, high-risk Medicare Part D 
beneficiaries included those with multiple chronic 
disease states, taking multiple Medicare Part D 
covered medications, and likely to incur an annual 
cost of USD3,000 for prescription medications.2 The 
MMA 2003 did not outline specific details of MTM 
services but mandated that MTM programs must be 
“designed to reduce the risk of adverse events, 
defined as a specific service or group of services 
performed by pharmacists or other healthcare 
providers that improves medication use and 
reduces adverse drug events”.3 Community 
pharmacists have been providing services similar to 
MTM for many years i.e., pharmaceutical care. 
However, unlike pharmaceutical care which does 
not have a reimbursement structure, MTM gives 
pharmacists the structure to provide services to 
Medicare Part D enrollees and receive 
reimbursement for these services. Although the 
MMA 2003 did not formally define MTM, a 
consensus of 11 national pharmacy organizations in 
2004 agreed that MTM is broadly defined as “a 
service or group of services that optimize 
therapeutic outcomes for individual patients”.4 
Expanding on this consensus, the American 
Pharmacists Association in partnership with the 
National Association of Chain Drug Stores 
Foundation outlined the specifics of MTM services.5   
Pharmacists in community pharmacies are afforded 
unique opportunities to provide numerous MTM 
services including but not limited to: patient 
education and potential drug therapy issues (e.g. 
adverse reactions, poor adherence, unnecessary 
therapy, generic substitution, and  not prescribed 
but necessary therapies based on disease state 
guidelines).    Many potential benefits come with 
pharmacist involvement in MTM services. First and 
foremost, therapeutic outcomes from pharmacist 
involvement in MTM programs have been widely 
researched and definitively shown to be beneficial 
for the patient.6-8 Additional studies have looked at 
the cost savings to the healthcare system from 
pharmacist involvement in medication management 
as well as the financial impact for pharmacies 
conducting MTM services. Ramalho de Oliveira 
showed an estimated savings of USD2,913,850 to 
an integrated health care system over a 10 year 
period.9 Another recent study evaluated net 
financial gains and losses for MTM services 
conducted by pharmacists and pharmacy students 
at an independent community pharmacy. During a 
16 month period the pharmacy had a net financial 
gain of USD3.28 for providing MTM services.10 
A study conducted in 2007 evaluated total 
medication cost savings from pharmacist 
interventions using a variety of delivery techniques 
including face-to-face encounters in a community 
pharmacy, phone interventions from a community 
pharmacy, a pharmacist-staffed call center, and 
direct patient education mailings.11 This study 
determined that drug product savings were highest 
when interventions were made in the community 
pharmacy setting, either face-to-face or telephonic 
as compared to interventions made by a pharmacist 
in a call center or educational mailing.  While this 
study specifically evaluated medication costs per 
patient, it only identified total drug product costs 
saved, not patient out-of-pocket expense. 
Previous studies have evaluated the acceptance 
rate of pharmacists’ interventions. DeName et al 
observed a 61.4% provider acceptance rate of 
pharmacists’ drug therapy recommendations in a 
freestanding pharmacist run clinic in Kentucky.12 
Another study examined prescriber acceptance of 
pharmacists’ drug therapy interventions in a 
community pharmacy. In this study prescribers 
accepted 47.4% of the pharmacists’ 
recommendations.13 
Balls Food Stores is a family-owned supermarket 
chain local to the Kansas City area. There are 28 
grocery stores with 20 pharmacies operating under 
both the Hen House and Balls Price Chopper 
banners. Balls Food Stores pharmacists (including 
residency trained and non-residency trained) and 
community pharmacy residents provide advanced 
patient care services including a travel vaccine 
clinic, immunizations (herpes zoster, pneumococcal 
and influenza), health screenings (osteoporosis, 
cholesterol, blood pressure, and blood glucose), 
and MTM Services. MTM services are offered to 
patients who are identified through the use of two 
separate third-party companies (Outcomes 
Pharmaceutical Health Care and Mirixa). These 
companies coordinate the provision of MTM 
services by contracting with Medicare Part D 
insurance plans to offer MTM services to the plan’s 
eligible beneficiaries, and then alert the community 
pharmacist that a patient is eligible for MTM 
services. Balls Food Stores pharmacists and 
community pharmacy residents also provide 
services for the company’s employee health 
initiative called Start Now. In the Start Now 
program, pharmacists and community pharmacy 
residents annually monitor Balls Food Stores 
employees’ blood pressure, blood glucose, 
cholesterol, height, weight, and waist 
circumference. Additionally with Start Now, 
employees participate in disease management 
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programs for diabetes and cardiovascular disease. 
There are also programs for lifestyle changes 
including weight management and smoking 
cessation.  
The primary objective of this study was to determine 
the net financial impact on patient out-of-pocket 
prescription medication expense as a result of 
community pharmacists’ MTM interventions. The 
secondary objective was to evaluate the patient and 
physician acceptance rates of the community 
pharmacists’ recommended MTM interventions. 
 
METHODS  
This study was approved by the Institutional Review 
Board of The University of Kansas Medical Center. 
Patients included in this study were Medicare Part D 
members who had been previously identified as 
eligible for MTM services by Outcomes 
Pharmaceutical Health Care. Interventions 
conducted by community pharmacists at 20 grocery 
store chain pharmacies from January 1, 2010 
through December 31, 2010 for MTM eligible 
patients were included in the study. Outcomes 
Pharmaceutical Health Care’s electronic database 
and the pharmacies’ prescription dispensing system 
records were used to collect the following data: age, 
gender, number of chronic prescription medications, 
number of interventions performed, patient and 
prescriber acceptance of suggested interventions 
and financial impact to the patient as a result of 
pharmacists’ interventions.  
The interventions assessed for this study included 
those which could potentially impact patient out-of-
pocket prescription medication expense by the 
addition, reduction, or elimination of a prescription 
medication. This included elimination of 
unnecessary drug therapy, generic substitutions, 
and identification and substitution to a preferred 
brand name medication based on the patient’s 
insurance plan payment tiers. In addition, this study 
evaluated prescription medication costs added as a 
result of pharmacists’ interventions such as the 
addition of needed therapies based on disease 
state guidelines, or any substitution in medication 
therapy which resulted in a higher out-of-pocket 
cost for the patient. Any other prescription 
medication therapy modification resulting in a 
change in out-of-pocket expense for the patient was 
also assessed, including changes as a result of 
drug-drug interactions, suboptimal drug selection, or 
adverse drug reactions. Interventions involving 
over-the-counter products were excluded from 
evaluation due to cost variation among these 
products. This study only evaluated direct 
prescription medication costs to the patient. Other 
costs avoided by the patient as a result of 
pharmacists’ interventions, such as the cost for an 
additional physician’s office visit, emergency room 
visit, or hospital stay were not evaluated. 
The patients’ and physicians’ acceptance rate of the 
pharmacist recommended MTM interventions was 
determined by evaluating electronic records 
completed by pharmacists performing MTM 
services. The pharmacists documented all 
interventions recommended to both patients and 
physicians and subsequently documented the 
patients and physicians responses to the 
recommended interventions.  
Inclusion and Exclusion Criteria 
Patients who participated in any aspect of MTM 
services during the study period of January 1, 2010 
through December 31, 2010 were included in this 
study. For the purposes of this study, MTM 
participants were defined as patients who 
participated in any aspect of MTM services, 
including comprehensive medication therapy 
reviews or any individual pharmacist interventions 
which were identified by both the pharmacists and 
Outcomes Pharmaceutical Health Care. 
Interventions were identified during the course of a 
comprehensive medication therapy review and also 
through routine encounters with the patient during 
traditional pharmacist dispensing workflow. Patients 
did not have to participate in every aspect of MTM 
services to be included in the study. Patients who 
refused any individual component of MTM services 
were still included if they consented to another 
pharmacist intervention or comprehensive 
medication therapy review session. Patients who 
refused all aspects of MTM services were excluded 
from the study.  
Data Analysis 
The financial impact of the MTM intervention from 
the patients’ perspective was calculated for each 
patient as an increase or decrease in patient out-of-
pocket expenses. Using SAS (version 9.2) this 
variable was assessed for normality. As the data 
was not normally distributed, a two-sided Wilcoxon-
Rank-Sum test and an a priori alpha level of 0.05 
was used to test the null hypothesis that the 




A total of 284 patients across 20 pharmacies were 
eligible for MTM services. Of these 284 patients, 
128 (45%) participated in MTM services and were 
included in this study (Figure 1). There were 116 
patients (41%) who declined all aspects of MTM 
services and 40 patients (14%) who were not 
offered MTM services. Patients who participated in 
MTM services were primarily female (72.7%) with a 
mean age of 74.4 years (SD=9.4) (Table 1). The 
mean number of baseline chronic prescription 
medications for these patients was 10.0 (SD=4.2).  
Overall, of the 128 patients included in the study 87 
(68%) did not see a direct financial impact from 
MTM services.  The remaining 41 (32%) patients 
had a change (increase or decrease) in out-of-
pocket expense: Thirty four (27%) of these patients 
saw a decrease in medication expenses, with an 
average cost reduction of USD440.50 (SD=289.69) 
Table 1. Baseline Characteristics for Patients 
Participating in MTM Services (n=128) 
Average Age in years (SD) 74.4 (9.4) 
Female (%) 72.7 
Baseline Medications (SD) 10.0 (4.2) 
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per patient per year. Seven (5%) patients 
experienced an increase in medication expenses 
with an average cost increase of USD255.66 
(SD=324.48) per patient per year. The net financial 
impact for all 128 patients was a savings of 
USD102.83 (SD=269.18) per patient per year 
(p<0.001).   No difference was found in the number 
of chronic prescription medications per patient 
compared to baseline. 
Pharmacists attempted a total of 732 interventions 
throughout the year for the 284 MTM eligible 
patients (Figure 2). Of all interventions attempted, 
53% (391/732) of these interventions were 
approved by both patient and physician, and among 
these approved interventions 17% (68/391) were 
deemed to have a potential financial impact on 
patient out-of-pocket expense. The most common 
intervention affecting out-of-pocket medication 
expenses was a change in medication (82%, 
56/68), followed by addition of a needed therapy 
based on disease state guidelines (12%, 8/68), and 
discontinuation of a duplicate or unnecessary 
therapy (6%, 4/68). Interventions which were found 
to not impact patient medication expenses included 
those involving patient education, dose change, and 
medication administration (i.e. inhaler technique). 
The remaining 47% of interventions (341/732) were 
not implemented due to patient or prescriber refusal 
of the pharmacist’s intervention.  Any financial 
impact resulting from medication adherence was not 




Our findings demonstrate that MTM services 
performed by community pharmacists are overall a 
cost savings event regarding patient out-of-pocket 
medication expenses. However, when a financial 
impact is realized, it is driven by only 32% of the 
patients. DeName et al showed similar results in a 
study involving patients within a health plan.12 The 
pharmacist interventions resulted in an average 
annual savings of USD166.20 to each patient and 
an annual savings to the health plan of USD163.08 
per patient. Another study conducted in an 
employer setting demonstrated an average direct 
savings to the employer of USD253 per patient per 
year as a result of pharmacist medication related 
interventions. These pharmacist interventions also 
saved the company an average of USD1011 per 
patient per year in direct and indirect health costs.14  
While our study demonstrated an overall decrease 
in out-of-pocket expenses as a result of MTM 
services, a few of our patients experienced an 
increase in out-of –pocket expenses. We believe it 
is possible that the costs added for patients in this 
study may actually provide a cost savings in the 
long-term through improved medication use. For 
example, the addition of an inexpensive angiotensin 
converting enzyme inhibitor (ACE) for blood 
pressure control and nephron-protection in a patient 
with diabetes may increase patient out-of-pocket 
expense immediately; however the benefit of the 
medication in preventing subsequent disease-
related complications may save the patient and the 
healthcare system significant costs in the future. Li 
et al reported that ACE inhibitors provide an overall 
cost-savings when used by patients with diabetes 
for hypertension control and to prevent ESRD.15  
This study also assessed the patients and 
prescribers acceptance rate of pharmacist 
interventions. The acceptance rate in this study was 
similar to the acceptance rates previously reported 
by similar studies. 
Limitations 
Our study had several limitations that warrant 
discussion. First, our study only assessed the 
financial impact for patients as a result of 
prescription medication expenses. We did not 
evaluate non-prescription medication changes due 
to wide cost variances of these products. Other 
factors that may have contributed to a financial 
savings for patients such as prevention of 
hospitalizations, emergency room visits, and 
doctors’ office visits were not assessed. Another 
limitation was our inability to assess medication 
adherence due to the limited time frame of this 
study. A potential increase in patient out-of-pocket 
expense exists if a patient had improved medication 
adherence as a result of pharmacists’ interventions 
and therefore re-filled a medication more frequently. 
However, as our study was restricted to a 12 month 
period, we could not fully assess the true impact of 
a medication adherence intervention, especially if 
the intervention had occurred late in the year. 
 
CONCLUSIONS 
In this community-based setting, patient 
participation in MTM services was found to be an 
overall cost savings event relative to patient out-of-
pocket medication expense. Future studies should 
evaluate changes in non-prescription medication 
expenses as a result of pharmacists’ interventions 
as well as prescription medication expenses. 
Likewise, future studies should evaluate medication 
adherence as improved adherence can significantly 
impact patient out-of-pocket medication expenses. 
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